PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 19226

A Phase Iii Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Gdc-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (Bo41843)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-ER (+), HER2 (-) locally advanced or metastatic breast cancer with measurable disease 
-No history of systemic therapy in the locally advanced or metastatic setting
-No recurrence during or within 12 months of neoadjuvant or adjuvant treatment with AI or CDK 4/6 inhibitor
-No prior treatment with fulvestrant (SERD)
-No history of clinically significant cardiac disease, HIV, or GI disease that effects absorption 

Available at: